SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus receives USFDA nod for Succinylcholine Chloride Injection, Plerixafor Injection

07 May 2018 Evaluate

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) multiple-dose vials. It is used as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

The group also received the tentative approval for Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), single-dose vial. It is used to mobilize hematopoietic stem cells into the bloodstream for their collection & subsequent transplantation in patients with certain type of blood cancers. It will be manufactured at Alidac Pharmaceuticals, a wholly owned subsidiary of Cadila Healthcare, located at the pharma SEZ in Ahmedabad.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group now has more than 190pprovals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences Share Price

938.90 -1.20 (-0.13%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×